Cost-Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation (NVAF) in Iran.
Amirmohammad TajikAzam AbbasiZahra GoudarziAzadeh Izadi-MoudMehdi VarmaghaniPublished in: Clinical cardiology (2024)
This study shows that Apixaban is a cost-effective option for stroke prevention in non-valvular atrial fibrillation patients in Iran compared to Warfarin.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- direct oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- end stage renal disease
- heart failure
- newly diagnosed
- ejection fraction
- percutaneous coronary intervention
- chronic kidney disease
- peritoneal dialysis
- blood brain barrier
- coronary artery disease
- aortic valve
- patient reported